Skip to content

Summit Therapeutics SMMT Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

Merck & Co. logo
Merck & Co.MRK
Exelixis logo
ExelixisEXEL
Incyte logo
IncyteINCY
Roivant Sciences logo
Roivant SciencesROIV
AbbVie logo
AbbVieABBV
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's common stock, shares issued (in shares)?
Summit Therapeutics (SMMT) reported common stock, shares issued (in shares) of $776.02M in Q1 2026.
How has Summit Therapeutics's common stock, shares issued (in shares) changed year-over-year?
Summit Therapeutics's common stock, shares issued (in shares) increased by 4.6% year-over-year, from $741.61M to $776.02M.
What is the long-term trend for Summit Therapeutics's common stock, shares issued (in shares)?
Over 5 years (2020 to 2025), Summit Therapeutics's common stock, shares issued (in shares) has grown at a 56.5% compound annual growth rate (CAGR), from $82.58M to $775.37M.